Due to the functional differences in the IL-23/IL-17 axis across chronic inflammatory conditions (85, 86), and the role of IL-23 in maintaining gut homeostasis and preventing obesity in animal models (87), studies on the effect of IL-23 blockade in metabolic outcomes in PsA patients are warranted. Here, IL17A is linked to obesity due to melanocortin 4 receptor deficiency.